{
    "nct_id": "NCT03029780",
    "official_title": "Phase II, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma",
    "inclusion_criteria": "* Advanced Renal Cell Carcinoma\n* Must have full activity or, if limited, must be able to walk and carry out light activities such as light house work or office work\n* Must have at least 1 lesion with measurable disease\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Subjects with active central nervous system metastases\n* Subjects who received prior therapy with checkpoint inhibitor\n* Subjects with active, known or suspected autoimmune disease\n\nOther protocol defined inclusion/exclusion criteria could apply",
    "miscellaneous_criteria": "For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com"
}